The therapy of eosinophilic granulomatosis with polyangiitis (EGPA) is challenging since currently available therapies,including corticosteroids and immunomodulators, are inadequate in controlling symptoms. The currently available therapies are also linked with significant morbidity and relapse.

In a new study, mepolizumab has been shown to be an effective add-on therapy with steroid-sparing effect in cases of relapsing or refractory EGPA. Intravenous immunoglobulin (IVIG) therapy is effective against mononeuritis multiplex or heart failure in patients with EGPA who do not respond to corticosteroid-cyclophosphamide treatment. It has been suggested that the earlier add-n treatment with a combination of IVIG and mepolizumab might be a useful adjunct treatment to induce clinical remission of EGPA and improve the rate of remission, reduce the relapse rate, and allow for lowered glucocorticoid use without any serious adverse drug effects.

Link: https://pubmed.ncbi.nlm.nih.gov/33305381/